Sage Therapeutics, Biogen get ZURZUVAE FDA approval for postpartum depression treatment
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) approved ZURZUVAE (zuranolone) 50 mg for adults ... Read More
Sage Therapeutics secures $3.1bn worth licensing deal for zuranolone and SAGE-217 with Biogen
Sage Therapeutics has secured a global collaboration and licensing deal worth up to $3.1 billion with Biogen for two of its drug candidates intended for ... Read More
ZULRESSO postpartum depression drug set to be launched in US by Sage Therapeutics
CNS biopharma company Sage Therapeutics is all set to commercially launch its ZULRESSO (brexanolone) injection in the US later this month for the treatment of ... Read More